This @-week , multicenter , parallel-arm study ( primary end point : @ weeks ) randomized patients ( @:@:@:@ ) to dulaglutide @ mg , dulaglutide @ mg , exenatide @ g , or placebo ( placebo-controlled period : @ weeks ) .